Published in
American Society of Hematology, Blood, 4(127), p. 411-419, 2016
DOI: 10.1182/blood-2015-08-664086
Links
- ORCID
- American Society of Hematology | PDF
- ORCID
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Journal article published in 2015 by
Harriet S. Walter 
,
Simon A. Rule,
Martin J. S. Dyer ,
Lionel Karlin,
Ceri Jones,
Bruno Cazin,
Philippe Quittet,
Nimish Shah,
Claire V. Hutchinson,
Hideyuki Honda,
Kevin Duffy,
Joseph Birkett,
Virginia Jamieson,
Nigel Courtenay-Luck,
Toshio Yoshizawa
and other authors.
,
Simon A. Rule,
Martin J. S. Dyer ,
Lionel Karlin,
Ceri Jones,
Bruno Cazin,
Philippe Quittet,
Nimish Shah,
Claire V. Hutchinson,
Hideyuki Honda,
Kevin Duffy,
Joseph Birkett,
Virginia Jamieson,
Nigel Courtenay-Luck,
Toshio Yoshizawa
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points We report a first-in-human dose-escalation study in relapsed/refractory B-cell malignancies with the potent BTK inhibitor ONO/GS-4059. ONO/GS-4059 induced clinically durable responses in relapsed/refractory B-cell malignancies without significant toxicities.